Natural history of angina pectoris in the Framingham study: Prognosis and survival

doi:10.1016/0002-9149(72)90624-8

The American Journal of Cardiology

Volume 29, Issue 2, February 1972, Pages 154-163

https://doi.org/10.1016/0002-9149(72)90624-8 Get rights and content

Abstract

The evolution of 303 cases of angina in a general population sample of 5,127 persons was ascertained and revealed that the lot of the angina victim is not a happy one. Prognosis as to survival and progression to more serious coronary manifestations was discouraging in men. One in 4 men with angina can expect to have a coronary attack within 5 years. The risk is half this for women. About 30 percent of those over 55 will die within 8 years, and 44 percent of the coronary deaths will be sudden. Mortality was close to that which follows the posthospital phase of myocardial infarction. Surprisingly, survival in men with uncomplicated angina was no better than that for angina which follows an infarction.

Angina was more likely to be the presenting complaint of coronary disease in women (65 percent) than in men (37 percent). In men 45 percent of angina arose out of myocardial infarction compared to 15 percent in women. Half of those sustaining initial myocardial infarctions had angina following it, 31 percent experiencing it for the first time. In those with angina who sustained an infarction, the angina disappeared in only 15 percent of men and no women, a rate lower than the 30 percent spontaneous rate of disappearance. Only 23 percent of infarctions were preceded by angina. Almost 1 in 4 myocardial infarctions were silent or went unrecognized. Such infarctions were rare in persons with prior angina.

References (17)

T Gordon et al.
Some methodologic problems in the long-term study of cardiovascular disease: observations on the Framingham Study
J Chronic Dis
(1959)
DW Richards et al.
Completed 25 year follow-up study of 456 patients with angina pectoris
J Chronic Dis
(1956)
WJ Zukel et al.
Survival following first diagnosis of coronary heart disease
Amer Heart J
(1969)
WB Kannel et al.
Factors of risk in the development of coronary heart disease: six year follow-up experience
Ann Intern Med
(1961)
TR Dawber et al.
An approach to longitudinal studies in a community: the Framingham study
Ann NY Acad Sci
(1963)
TR Dawber et al.
An epidemiologic study of heart disease: the Framingham study
Nutr Rev
(1958)
CL Chiang
On the probability of death from specific causes in the presence of competing risks
JW Hurst et al.
The Heart

There are more references available in the full text version of this article.

Cited by (398)

A Comprehensive Review: Epidemiological Strategies, Catheterization and Biomarkers used as a Bioweapon in Diagnosis and Management of Cardio Vascular Diseases
2023, Current Problems in Cardiology
Coronary artery disease (CAD) is a serious health problem that causes a considerable number of mortality in a number of affluent nations throughout the world. The estimated death encountered in many developed countries includes including Pakistan, reached 111,367 and accounted for 9.87% of all deaths, despite the mortality rate being around 7.2 million deaths per year, or 12% of all estimated deaths accounted annually around the globe, with improved health systems. Atherosclerosis progressing causes the coronary arteries to become partially or completely blocked, which results in CAD. Additionally, smoking, diabetes mellitus, homocystinuria, hypertension, obesity, hyperlipidemia, and psychological stress are risk factors for CAD. The symptoms of CAD include angina which is described as a burning, pain or discomfort in the chest, nausea, weakness, shortness of breath, lightheadedness, and pain or discomfort in the arms or shoulders. Atherosclerosis and thrombosis are the 2 pathophysiological pathways most frequently involved in acute coronary syndrome (ACS). Asymptomatic plaque disruption, plaque bleeding, symptomatic coronary blockage, and myocardial infarction are the prognoses for CAD. In this review, we will focus on medicated therapy which is being employed for the relief of angina linked with CAD including antiplatelet medicines, nitrates, calcium antagonists, blockers, catheterization, and the frequency of recanalized infarct-related arteries in patients with acute anterior wall myocardial infarction (AWMI). Furthermore, we have also enlightened the importance of biomarkers that are helpful in the diagnosis and management of CAD.
A 30-year trend of ischemic heart disease burden in a developing country; a systematic analysis of the global burden of disease study 2019 in Iran
2023, International Journal of Cardiology
Evaluating the burden of ischemic heart disease (IHD) as the first cause of mortality worldwide is necessary to develop healthcare policies. This study aimed to report the national and subnational IHD burden and risk factors in Iran according to the Global Burden of Disease (GBD) study 2019.
We extracted, processed, and presented the results of the GBD 2019 study regarding incidence, prevalence, deaths, years lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life years (DALYs), and attributable burden to risk factors of IHD in Iran during 1990–2019.
Age-standardized death and DALY rates decreased by 42.7% (95% uncertainty interval, 38.1–47.9) and 47.7% (43.6–52.9) during 1990–2019, slower since 2011 and reached 163.6 deaths (149.0–176.2), 2842.7 DALYs (2657.0–3103.1) per 100,000 persons in 2019. Meanwhile, with a lower reduction of 7.7% (6.0–9.5), the incidence rate reached 829.1 new cases (719.9–945.2) per 100,000 persons in 2019. High systolic blood pressure and elevated low-density lipoprotein cholesterol (LDL-C) contributed to the highest deaths, and DALYs age-standardized rates in 1990 and 2019. They followed by high fasting plasma glucose (FPG), and high body-mass index (BMI) with an upward trend of contribution from 1990 to 2019. A convergence pattern in the provincial death age-standardized rate was observed, with the lowest rate in Iran's capital city; 84.7 deaths per 100,000 (70.6–99.4) in 2019.
The incidence rate reduced remarkably lower than the mortality rate, which necessitates promoting primary prevention strategies. Also, interventions should be adopted to control growing risk factors like high FPG, and high BMI.
Preliminary Feasibility of Stress Myocardial Elastography for the Detection of Coronary Artery Disease
2023, Ultrasound in Medicine and Biology
Myocardial elastography (ME) is a cardiac strain imaging technique that has been found capable of detecting a decrease in radial strain caused by ischemia or infarction in patients with coronary artery disease (CAD) as well as in a canine model. Prior studies have focused on rest imaging, but stress testing can reveal functional deficits caused by stenoses that are asymptomatic at rest. Therefore, it has been proposed that stress ME (S-ME) improves the detection of CAD. A novel strain difference (Δε) metric is presented and investigated in a canine model of induced ischemia, as well as in a study in human patients with CAD validated by myocardial perfusion imaging. In the canine model study, flow-limiting stenosis was induced by partial ligation in n = 2 canines, and stenosis was found to consistently reduce Δε in the affected myocardial regions compared with baseline, as well as compared to myocardial regions that are remote to the induced stenosis. In the clinical study, the median Δε was significantly lower (p < 0.05) in infarcted myocardial regions (–6.29%) than in those with normal perfusion (4.62%), with Δε in ischemic regions falling in between (–2.91%). The same trend was observed when considering radial strain during stress and, to a lesser degree, at rest alone. The results indicate that S-ME may be more sensitive to mild cases of CAD that are functionally asymptomatic at rest.
Risk factors differ by first manifestation of cardiovascular disease in type 1 diabetes
2020, Diabetes Research and Clinical Practice
We compared risk factors for three CVD manifestations and a composite outcome over 25 years’ follow-up in the Pittsburgh Epidemiology of Diabetes Complications (EDC) prospective cohort study of childhood-onset (<17 years) type 1 diabetes (n = 658).
First CVD manifestations examined were: (1) major atherosclerotic cardiovascular event (MACE, i.e. CVD death, myocardial infarction, stroke), (2) coronary revascularization, (3) soft coronary artery disease (CAD, i.e. ischemia ECG, angina), and a (4) composite (MACE + revascularization) outcome. Baseline and time-varying mean and current risk factors, including medication use, were assessed, in diabetes duration-adjusted models.
MACE (n = 107) was predicted by ln(albumin excretion rate) (AER, HR = 1.3, p < 0.0001), systolic BP (SBP, HR = 1.03, p < 0.0001), white blood cell count (WBC, HR = 1.2, p < 0.0001), HbA1c (HR = 1.2p = 0.03), LDLc (HR = 1.01, p = 0.03). Soft CAD (n = 91) was predicted by ln(AER) (HR = 1.2, p = 0.004), SBP (HR = 1.03, p = 0.0002), WBC (HR = 1.2, p = 0.0003), HbA1c (HR = 1.2, p = 0.005). Revascularization (n = 38) was predicted by LDLc (HR = 1.03, p < 0.0001), eGFR (HR = 0.98, p = 0.002), HbA1c (HR = 1.3, p = 0.03). Adding revascularization to MACE enhanced the role of LDLc, while diminishing that of HbA1c, compared to MACE alone.
Important risk factor associations may be affected by examining composite CVD outcomes. More research is needed to determine how to best incorporate revascularization into composite CVD definitions.
6.16 Biomaterials for cardiac cell transplantation
2017, Comprehensive Biomaterials II
Regenerative therapy for heart failure remains a significant unmet need sin the global medical community. One of the leading causes of heart failure is myocardial infarction (MI), which occurs following blockage of the coronary arteries, causing a loss of cardiac muscle and replacement with non-contractile scar. Overtime, this results in a process of remodeling which leads to left ventricular (LV) dilation and dysfunction. Novel approaches for treatment of this condition are needed to improve the quality of life and the survival of patients who suffer from post-MI LV dysfunction and congestive heart failure (CHF). The transplantation of stem cells has been proposed as a therapeutic option to improve clinical outcome and may significantly improve regional contractile and left ventricular function. However, most stem cell transplantation studies have yielded modest results, with cell death or displacement by the heart’s contractions a significant impediment to cell engraftment and improved therapeutic outcome. Collectively, these observations suggest the success of cell transplantation for cardiac tissue regeneration will hinge upon the development of matrices to promote their functional integration into existing tissue, and the subsequent expansion of transplant size. Accordingly biomaterials are now being explored to address these issues, creating pro-survival systems for stem cell transplantation comprised of natural, synthetic, and advanced biosynthetic hybrid materials.
Oral sirolimus: A possible treatment for refractory angina pectoris in the elderly
2016, International Journal of Cardiology
Refractory angina pectoris (RAP) is a clinical problem, frequently encountered in the elderly, associated with high health-care costs. Until recently, the goal of RAP treatment aimed at improving the quality of life (QoL) because it was thought that mortality rates were not different between stable angina pectoris and RAP. Our purpose was at determining whether any mortality rate difference exists and whether any novel therapeutical solution might be translated into clinical practice. We therefore performed a literature review to assess current optimal treatment of RAP patients, including all studies involving the use of oral sirolimus and stents, although no consistent evidence was found for any specific treatment to improve survival, apart from minor QoL amelioration. A large mortality difference was seen between RAP and stable angina pectoris. On the other hand, therapeutic approaches to RAP patients showed frequent complications and several contraindications, depending on the procedure.
We propose to inhibit instead of stimulating angiogenesis, by giving oral sirolimus, an immunosuppressive drug, thereby decreasing the atherosclerotic process and its evolution. Sirolimus was shown to decrease left ventricular mass (thus indirectly decreasing myocardial oxygen needs and consumption). It might stop and, in some cases, even enable regression of plaque progression. Sirolimus side effects are mild to moderate and wash-out rapidly at treatment discontinuation. Compared with current therapies sirolimus treatment is more health-care cost efficient. It should be important to design a trial in RAP patients powered to reduce mortality and QoL increase.

View all citing articles on Scopus

View full text

Clinical studyNatural history of angina pectoris in the Framingham study: Prognosis and survival

Abstract

J Chronic Dis

J Chronic Dis

Amer Heart J

Factors of risk in the development of coronary heart disease: six year follow-up experience

Ann Intern Med

An approach to longitudinal studies in a community: the Framingham study

Ann NY Acad Sci

An epidemiologic study of heart disease: the Framingham study

Nutr Rev

On the probability of death from specific causes in the presence of competing risks

The Heart

Clinical study
Natural history of angina pectoris in the Framingham study: Prognosis and survival